EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting protein-protein interactions for therapeutic intervention in Parkinson's disease to delay progression.

Hassaan Ahmad Ahmad, Syeda Farwa Zaidi, Abdullah Jan Safi Jan Safi, Sadaqat Ullah Rehmat, Safi Ullah, Summet Kumar

Innovative Research in Applied, Biological and Chemical Sciences · 2024

DOI: 10.62497/irabcs.2024.37 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Innovative Research in Applied, Biological and Chemical Sciences, 2024. Verfasst von Hassaan Ahmad Ahmad und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson's disease (PD) is a neurodegenerative condition with few treatments to slow or stop development. Protein-protein interactions (PPIs) are intriguing therapeutic targets. This research examined the safety and effectiveness of a new Parkinson's disease medication targeting PPIs.

Methods

After enrollment, 60 individuals were randomly assigned to the treatment and control groups. MDS-UPDRS Part III score change from baseline to week 12 was the main outcome measure. Secondary outcome measures were the Hoehn and Yahr scale, NMSS, and Montreal Cognitive Assessment. Study-wide adverse events were tracked.

Results

Compared to the control group, the treatment group exhibited a substantial improvement in MDS-UPDRS Part III score (p < 0.001). Additionally, the therapy group showed substantial improvements in Hoehn and Yahr stage, NMSS score, and MoCA score compared to the control group (p < 0.001). No significant adverse effects were documented with the experimental medication.

Conclusion

This research suggests that targeting PPIs may treat Parkinson's disease. No harmful side effects were detected with the experimental medication, which improved motor and non-motor symptoms in PD patients. These results require more study to determine the long-term safety and effectiveness of targeting PPIs in Parkinson's disease.

Zitieren

APA

Ahmad, H. A., Zaidi, S. F., Safi, A. J. S. J., Rehmat, S. U., Ullah, S., & Kumar, S. (2024). Targeting protein-protein interactions for therapeutic intervention in Parkinson's disease to delay progression. Innovative Research in Applied, Biological and Chemical Sciences. https://doi.org/10.62497/irabcs.2024.37

Vancouver

Ahmad HA, Zaidi SF, Safi AJSJ, Rehmat SU, Ullah S, Kumar S. Targeting protein-protein interactions for therapeutic intervention in Parkinson's disease to delay progression. Innovative Research in Applied, Biological and Chemical Sciences. 2024. doi:10.62497/irabcs.2024.37

BibTeX
@article{Ahmad2024,
  author = {Ahmad, Hassaan Ahmad and Zaidi, Syeda Farwa and Safi, Abdullah Jan Safi Jan and Rehmat, Sadaqat Ullah and Ullah, Safi and Kumar, Summet},
  title = {Targeting protein-protein interactions for therapeutic intervention in Parkinson's disease to delay progression},
  journal = {Innovative Research in Applied, Biological and Chemical Sciences},
  year = {2024},
  doi = {10.62497/irabcs.2024.37}
}
Kostenlos starten →